Background: A chronic acquired hypermelanosis of the skin, melasma is characterized by uniformly distributed muddy brown macules on sun-exposed areas of the body, particularly the face. The edges of the lesions are serrated, and they are frequently limited to the face, including the cheeks. The present study was conducted to assess the oral versus intradermal Tranexamic acid infusion for the treatment of melasma. Materials & Methods:78 patients of melasma of both genderswere divided into 2 groups of 39 each. Patients in group I were given tablet tranexamic acid (250 mg) twice daily for 3 months. In group II, patients were administered intradermal injections of tranexamic acid. Results: Depth was dermal in 8 and 7, and epidermal in 11 and 13 patients and mixed in 20 and 19 patients in group I and II respectively. Fitzpatrick type II was seen in 5 and 7, III in 23 and 22, and IV in 11 and 10 patients in group I and II respectively. Pattern was Centrofacial in 24 and 20, mandibular in 17and 18 and dermal in 10 and 12 patients in group I and II respectively. The difference was non- significant (P> 0.05). In group I and group II, the mean MASI score at 1st sitting was 4.78 and 4.64, at 2nd sitting was 3.02 and 3.74, at 3rd sitting was 2.12 and 2.36, at 4th sitting was 2.14 and 2.75, at 5th sitting was 1.84 and 1.34 and at 6th sitting was 2.03 and 2.52 respectively. The difference was significant (P< 0.05). Conclusion: For the treatment of melasma, tranexamic acid is a medication that is both safe and well tolerated. Melasma can be effectively administered orally or intradermally. The mean MASI scores for both Group 1 and Group 2 significantly decreased from the first to the fifth sitting, indicating that the severity of their melasma improved over time. However, because the MASI scores for each group was consistent, there were no appreciable variations in the magnitude of this improvement between the two groups.